Olubukola Ayodele: Day 1 of ESMO 2023 was all about early breast cancer (EBC) for me today

Olubukola Ayodele, Consultant Medical Oncologist at University Hospitals of Leicester NHS trust, shared on LinkedIn:

“Day 1 of ESMO 2023 is over.

It was all about early breast cancer (EBC) for me today.

• MonarchE continues to show benefit with adjuvant Abemaciclib in HR+/HER2- EBC. Median follow up 54 months. All patients have completed 2 years of treatment. Close follow up needed as this cohort tend to relapse after the 5 year mark.
• KN522 also continues to show benefit of the addition of pembrolizumab to chemotherapy for TNBC irrespective of stage.
• New territory: Neoadjuvant immunotherapy in combination with chemotherapy in high risk HR+/HER2- EBC. pCR benefit seen but will it translate to EFS? Also, higher benefit seen in PD-L1 + patients. Would this influence the FDA/EMA approval if benefit is consistent?

More biomarker analysis needed to better select patients in EBC.
However, I’m so happy to see more potential treatment options for patients.”

Source: Olubukola Ayodele/LinkedIn